USFDA Advisory Committee votes n Lynparza plus Abiraterone and Prednisone for prostate cancer

The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients

CPHI & PMEC China 2023 to see surge from pent up international ingredients demand

China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey

Lilly's Lebrikizumab shows improved face or hand dermatitis

Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients

CHMP recommends EU approval of Roche’s fixed-duration Columvi for large B-cell lymphoma

Once approved, Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphoma

Aptar Digital Health and Healint collaborate for Central Nervous System

The partnership will capitalize on the combined capabilities of the two organizations

Atul appoints Rangaswamy Iyer as Independent Director

The appointment is effective from May 01, 2023 for five years

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness

PI Industries announces twin acquisitions into Pharma API & CDMO space

Yuyu Pharma unveils the results of its studies for its dry eye treatment peptide

The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science

Yasmin and Mirena to take back seat from Bayer’s future drug strategy, says GlobalData

The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework